Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis

Experimental Parasitology

Volumn 121, Issue 1, 2009, Pages 69-75

  Narayan, S ^a   Bimal, S ^a   Singh, Shubhankar K ^a   Gupta, A K ^a   Singh, V P ^a   Sinha, P K ^a   Das, P ^a  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

IFN; IL 10; IL 4; Interferon; Interleukin 10; Interleukin 4; Leishmania donovani; PBMC; Peripheral blood mononuclear cell; SAG NR; SAG R; Sodium antimony gluconate non responder; Sodium antimony gluconate responder; Visceral Leishmaniasis; VL

Indexed keywords

ANTIMONY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4;

AMASTIGOTE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; LEISHMANIA DONOVANI; MACROPHAGE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CYTOKINES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES;

LEISHMANIA DONOVANI; MUS;

EID: 57149090265     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2008.09.015     Document Type: Article

References (37)

1. Bimal S., Singh S.K., Sinha S., Pandey K., Sinha P.K., Ranjan A., Bhattacharya S.K., and Das P. Leishmania donovani: Role of CD2 on CD4 + T-cell function in visceral leishmaniasis. Experimental Parasitology 118 (2008) 238-246
2. Carrera L., Gazzinelli R.T., Badolata R., Hiney S., Muller W., Kuhu R., and Sacks D.L. Leishmania promastigotes selectively inhibit Interleukin-12 induction in bone marrow-derived macrophages from susceptible and resistant mice. Journal of Experimental Medicine 183 (1996) 515-526
3. Carvalho E.M., Bacellar O., Brownell C., Regis T., Coffman R.L., and Reed S.G. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. Journal of Immunology 152 (1994) 5949-5956
4. Chang K.P. Human cutaneous leishmania in a mouse macrophages line: Propagation and Isolation of Intracellular parasites. Science 209 (1980) 1240-1242
5. D'Andrea A., Aste M., Valiante N., Kubin M., and Trinchieri G. Interleukin-10 inhibits human lymphocyte interferon-γ production by suppressing interleukin-12 synthesis in accessory cells. Journal of Experimental Medicine 178 (1993) 1041-1050
6. Das V.N.R., Ranjan A., Bimal S., Siddique N.A., Pandey K., Kumar N., Verma N., Singh V.P., Sinha P.K., and Bhattacharya S.K. Magnitute of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. The National Medical Journal of India 18 (2005) 131-133
7. Desjeux. The increase in risk factors for leishmaniasis world wide. Transactions of the Royal Society of Tropical Medicine and Hygiene 95 (2001) 239-243
8. Ghalib H.W., Piuvezam M.R., Skeiky Y.A.W., Suddif M., Hashim F.A., EL-Hussan A.M., and Reed S.G. Interleukin-10 production correlates with pathology in human Leishmania donovani infections. The Journal of Clinical Investigation 92 (1993) 324-329
9. Gottesman M.M., Fojo T., and Bates S.E. Multi drug resistance in cancer: Role of ATP dependent transporters. Nature Review of Cancer 2 (2002) 48-58
10. Harith A.E., Kolk A.J.H., Kager P.A., Leeuwenburg J., Muigui R., Kiugu S., and Laarman J.J. A simple and economical direct agglutination test for serodagnosis and seroepidemiological studies of visceral Leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 80 (1986) 583-587
11. Hondwicz B., and Scott P. Influence of parasite load on the ability of type1 T cells to control Leishmania major infection. Infection and Immunity 70 (2002) 498-503
12. Jha T.K., Sunder S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., and Berman J. Miltifosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine 341 (1999) 1795-1800
13. Lal C.S., Gupta A.K., Das V.N.R., Verma N., Sinha N.K., Singh R., Palit A., and Kar S.K. Isoenzyme typing of Leishmania parasites of different geographical distribution in Bihar. Journal of Parasitic Diseases 23 (1999) 27-30
14. Li J., Nolan T.J., and Forrell J.P. Leishmania major: A clone with low virulence for BALB/c mice elicit a Th1 type response and protects against infection with a higher virulent clone. Experimental Parasitology 87 (1997) 47-57
15. Mookerjee Basu J., Mookerjee A., Banarjee R., Saha M., Singh S., Naskar K., Tripathy G., Sinha P.K., Pandey K., Sunder S., Bimal S., Das P.K., Choudhuri S.K., and Roy S. Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection. Antimicrobial Agents and Chemotherapy 52 (2008) 1080-1093
16. Mookerjee Basu J., and Roy S. Sodium antimony gluconate (SAG) mediates antileishmanial effect by stimulating innate and cellular arms of the immune system. Science Culture 73 (2007) 138-143
17. Murray H.W. Clinical and experimental advances in treatment of 'Visceral leishmaniasis'. Antimicrobial Agents and Chemotherapy 45 (2001) 2185-2197
18. Murray H.W., Christina M.L., Mauze S., Freeman S., Moreira A.L., Kaplan G., and Coffman R.L. Interleukin-10 (IL-10) in Experimental visceral leishmaniasis and IL-10 Recepter Blockade as Immunotherapy. Infection and Immunology 70 (2002) 6284-6293
19. Murray H.W., and Delph-Etienne S. Role of endogenous gamma interferon and macrophage microbial mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infection and Immunology 68 (2000) 288-293
20. Murray H.W., Oca M.J., Granger A.M., and Schreiber R.D. Successful response to chemotherapy in experimental visceral leishmaniasis: requirement for T cells and effect of lymphokines. The Journal of Clinical Investigation 83 (1989) 1254-1259
21. Ouellette M., Legare D., Haimeur A., Grondin K., Roy G., Brochu C., and Papadopoulou B. ABC tranporters in Leishmania and their role in drug resistance. Drug Resistant Updates 1 (1998) 43-48
22. Prussin C., and Mecalft D. Detection of Intracytoplasmic cytokine using flowcytomery and ditectly conjugated antibodies. Journal of Immunology Methods 188 (1995) 117-128
23. Reed S.G., Badaro R., and Lloyd R.M.C. Identification of specific and crossreactive antigens of Leishmania donovani chagasi by human infection serum. Journal of Immunology 138 (1987) 1596-1602
24. Reiner N.E., Ng W., Wilson C.B., McMaster W.R., and Burchett S.K. Modulation of in vitro Monocyte Cytokine Responses to Leishmania donovani. Interferon-γ prevents parasite-induced inhibition of Interlukine1 Production and Primes Monocytes to Respond to Leishmania by Producing Both Tumor Necrocis Factor-α and Interleukin-1. The Journal of Clinical Investigation 85 (1990) 1914-1924
25. Reiner S.L., and Locksley R.N. The regulation of immunity to Leishmania major. Annual Review Immunology 13 (1995) 151-177
26. Saha S., Mandal S., Ravindran R., Bhowmick S., Modak D., Mallick S., Rahman M., Kar S., Goswami R., Guha S.K., Pramanik N., Saha B., and Ali N. IL-10 and TGF beta mediated susceptibility in kala-azar and post kala-azar dermal leishmaniasis the significance of amphotericin B in the control of Leishmania donovani infection in India. Journal of Immunology 179 (2007) 5592-5603
27. Scott P., Natovitz P., Coffman R.L., Pearce E., and Sher A. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T-helper subsets and respond to distinct parasite antigens. The Journal of Experimental Medicine 168 (1988) 1675-1684
28. Singh N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian Journal of Medical Research 123 (2006) 411-422
29. Singh N., Singh R.T., and Sunder S. Identification of a gene linked to drug resistance in field isolates of Leishmania donovani. Annals of Tropical Medicine and Parasitology 96 (2002) 839-841
30. Singh N., Singh R.T., and Sunder S. Novel mechanism of drug resistance in kala-azar field isolates. Journal of Infectious Diseases 188 (2003) 600-607
31. Sunder S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., Kumar P.C.K., and Murray H.W. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epedimic. Clinical Infectious Diseases 31 (2000) 1104-1107
32. Sunder S., Sahu M., Mehta H., Gupta A., Kohli U., Rai M., Berman J.D., and Murray H.W. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clinical Infectious Diseases 35 (2002) 581-586
33. Sunder S., Singh V.P., Sharma S., Makharia M.K., and Murray H.W. Response to Intreferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious Diseases. 176 (1997) 1117-1119
34. Thakur C.P., Mitra D.K., and Narayan S. Skewing of cytokine profile towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate. Transactions of the Royal Society of Tropical Medicine and Hygiene 97 (2003) 409-412
35. Thakur C.P., and Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first line drugs in the treatment of Indian visceral leishmaniasis. Annals of Tropical Medicine and Parasitology 98 (2004) 129-138
36. Thakur C.P., Sinha G.P., Pandey A.K., Kumar N., Kumar P., Hassan S.M., Narain S., and Roy R.K. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar., India. Justify its continued use as a first line drug ? An observational study of 80 cases. Annals of Tropical Medicine and Parasitology 92 (1998) 561-569
37. Uzonna J.E., Brestscher P., Wei G., and Yurkowski D. Immune elimination of Leishmania major in mice: Implications for immune memory, vaccination and reactivation disease. Journal of Immunology 167 (2001) 6967-6974